Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine Nerve Blocks for Persistent Postherniorrhaphy Pain
NCT01373593Phase 4
Key facts
- Status
- Terminated
- Start
- Jan 2011
- Primary completion
- Jul 2011
- Countries
- 1
- Sponsor
- Rigshospitalet
- Modality
- Small Molecules
- Drugs
- lidocaine
- Conditions
- post herniorrhaphy pain syndrome (PHPS)
01
Overview
Phase 4, randomised, double-blind trial in post herniorrhaphy pain syndrome (PHPS) comparing Lidocaine Arm with Placebo Arm (2 arms). Primary endpoints: Pain perception, Sensory mapping and 1 more. Started Jan 2011; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Lidocaine Arm
Patients receive lidocaine block in one period and placebo in the other.
Placebo Arm
Patients receive placebo block in one period and lidocaine in the other.
03
Who it enrols
Patients older than 18 years with severe persistent postherniorrhaphy pain (NRS > 6) for more than 6 months, excluding those with amide local anesthetic allergy or recurrent hernia.
04
Endpoints
Primary
Pain perception
Sensory mapping
Quantitative Sensory Testing
Beyond the preview
Go deeper on NCT01373593.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373593.